Concord Biotech Ltd IPO
Open Demat Account
Concord Biotech Ltd IPO Details
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| ₹ 209.26 L | ₹ 209.26 L | ₹ 73.2 L | ₹ 307.56 L | BSE | ₹ 1550.59 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 04 Aug, 23 | 08 Aug, 23 | 20 | ₹ 14,100 | Book Building | 18 Aug, 23 |
Concord Biotech Ltd IPO Dates
Details
| Sector | Type |
|---|---|
| Sector | Pharmaceuticals - Indian - Bulk Drugs & Formln |
| Sub Sector | NA |
| Issue Type | Book Building |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
|---|---|---|---|
| QIB | 0x | 10457826 | 0 |
| NII | 0x | 3137348 | 0 |
| Retail | 0x | 7320478 | 0 |
| Employee | 0x | 10000 | 0 |
| Total | 0x | 20925652 | 0 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Concord Biotech Ltd Financial Status
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 1,016.94 | 853.17 | 712.93 |
| EBITDA | 516.38 | 428.12 | 341.26 |
| PAT | 304.73 | 238.13 | 178.57 |
| Total Assets | 654.98 | 592.95 | 561.14 |
| Share Capital | 10.46 | 10.46 | 9.51 |
| Total Borrowings | 56.62 | 94.67 | 105.51 |
| Operating Activities (Net Cash) | 358.32 | 292.16 | 228.62 |
| Investing Activities (Net Cash) | 32.89 | -34.98 | 0.23 |
| Financing Activities (Net Cash) | 56.62 | 94.67 | 105.51 |
| Net Cashflow | 47.02 | 43.45 | 88.93 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Concord Biotech Ltd
Concord Biotech Limited was originally incorporated as `Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 23, 1984, issued by the Registrar of Companies, Gujarat, at Ahmedabad (RoC). Thereafter, an application dated June 24, 1985 was filed for undertaking the change in the name of the company to Concord Pharmaceuticals Private Limited', pursuant to which a revised certificate of incorporation dated September 24, 1985 was issued by the RoC. Subsequently, with effect from December 26, 1986, Concord Pharmaceuticals Private Limited deemed to have become a public company pursuant to Section 43A of Companies Act, 1956. Thereafter, the name of the Company was changed to 'Concord Biotech Limited' and a fresh certificate of incorporation dated February 16, 2001 was issued by the RoC. Subsequently, the Company became a public company from a deemed public company and a fresh certificate of incorporation dated November 7, 2001 was issued by the RoC.
The oncology drug market is the largest segment among the therapeutic areas in the API market, with a sales value of USD 42 billion (Rs.3,466 billion) in 2022. The anti-infectives market is one of the largest segments by sales value among the therapeutic areas in the API market, with a sales value of USD 32 billion (Rs. 2,643 billion) in 2022. Immunosuppressants market was valued at USD 16 billion (Rs. 1,298 billion) and the global small molecule fermentation API market was valued at USD 11 billion (Rs. 925 billion) in 2022.
Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022. The Company had (i) 23 APIs across immunosuppressants, oncology and anti-infectives, and (ii) 77 approved products for formulations. The Company has over 200 customers in over 70 countries as of March 31, 2023 for its APIs and formulations.
Peer Comparison:
- Divi's Laboratories Ltd
- Suven Pharmaceuticals Ltd
- Laurus Labs Ltd
- Shilpa Medicare Ltd
Concord Biotech Ltd IPO Key Points
Strengths
- Established presence across the complex fermentation value chain;
- Global leadership in immunosuppressant APIs along with a wide spectrum of complex fermentation-based APIs across multiple therapeutic areas;
- Scaled manufacturing facilities with a consistent regulatory compliance track record and supported by strong R&D capabilities;
- Diversified global customer base with long-standing relationships with key customers;
- Experienced Promoters, management team supported by marquee investors;
Risk
- Any delay, interruption or reduction in the supply of its raw materials or the transportation of the company raw materials or products may adversely impact the pricing and supply of its products and have an adverse effect on its business.
- Any manufacturing or quality control issues may damage its reputation, subject it to regulatory action, and expose the company to litigation or other liabilities, which could adversely affect its business, financial condition and results of operations.
- A slowdown or shutdown in its manufacturing or research and development operations, all located in Gujarat, India, could adversely affect the company business, financial condition and results of operations.
Strategy
- Continue to increase our API market share and further develop its portfolio of complex and niche APIs with high growth potential.
- Increase the presence of its existing formulations and expand into new formulations.
- Improve cost management and operational efficiencies.
- Grow its CDMO business.
- Established presence across the complex fermentation value chain;
- Global leadership in immunosuppressant APIs along with a wide spectrum of complex fermentation-based APIs across multiple therapeutic areas;
- Scaled manufacturing facilities with a consistent regulatory compliance track record and supported by strong R&D capabilities;
- Diversified global customer base with long-standing relationships with key customers;
- Experienced Promoters, management team supported by marquee investors;
How To Apply for Concord Biotech Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.
